Theravance Biopharma, Inc.TBPHNASDAQ
Loading
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +6.77% | +6.10% | +83.75% | +18.51% | +144.70% |
| Gross Profit Growth | +102.70% | -28.89% | +265.06% | +56.29% | -100.00% |
| EBITDA Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Net Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Diluted Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Weighted Average Shares Growth | -0.22% | +2.95% | +2.93% | +3.02% | +3.17% |
| Weighted Average Shares Diluted Growth | -0.22% | +2.95% | +4.06% | +5.85% | +7.60% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Free Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Receivables Growth | +291.67% | +4.70% | +53.29% | +8.44% | -100.00% |
| Inventory Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Asset Growth | -7.29% | -7.47% | +17.68% | +16.67% | +37.10% |
| Book Value per Share Growth | -17.40% | -21.30% | +12.78% | +21.65% | +168.11% |
| Debt Growth | +1.34% | +0.53% | -0.44% | -0.86% | -36.25% |
| R&D Expense Growth | +5.09% | +27.70% | +5.38% | -12.47% | -22.12% |
| SG&A Expenses Growth | +16.73% | +0.00% | +0.00% | +0.00% | +0.09% |